Science fraud draws attention, but most scientists think it’s a far lesser threat to their field than the many times researchers cut corners.

Taking potshots at some scientific research is a pastime of American politics. But critics need to assess the merits of the research they target beforehand.

Peer review is a thankless task, but journals have been experimenting with accolades and cash incentives for scientists who serve as peer reviewers.

An editorial argues that data sharing can cripple scientific progress and harm patients, but there are myriad flaws with that reasoning.

The impact factor is a poor measure of a journal's quality, and academics say it should either be overhauled or done away with entirely.

Research papers in the life sciences have become increasingly dense, potentially making them harder for reviewers to understand.

Can scientists who commit research fraud be rehabilitated? One program is trying to keep ex-fraudsters from falling off the wagon.

A homeopathy journal was recently booted from the list of respectable scientific titles — but why was it among the ranks in the first place?

Science appears to be in something of an evolutionary cul-de-sac, mired in poor methodology and misguided objectives that have changed only for the worse.

The current movement to replicate results is crippled by a lack of agreement about the very nature of the word “replication” and its synonyms.

Scientists, journal editors, and funders of research are talking about a once-heretical idea: preprint publishing for biologists.

Entrepreneurs in Silicon Valley live by the motto of “Fail fast, fail often." Scientists would do well to likewise embrace failure.

An outspoken biologist uses social media as a megaphone as he calls out his colleagues for hyping their research findings and ignoring women scientists.

As the White House prepares for its annual science fair, it's worth remembering that these events leave some children behind.

Two high-profile cases in which universities — who by US law are the ones that must open an investigation into misconduct — stonewalled the effort.

Dozens of startups, backed by hundreds of millions in investment, are racing to develop a liquid biopsy that could diagnose cancer from a simple blood draw.